Medical Problems in Pregnant Women

Main Article Content

Michèle Mahone MSc MD
Nadine Sauvé MD

prescription of a new drug during pregnancy, thromboprophylaxis for asymptomatic thrombophilias, thrombophilia screening, prevention for placental complications

Abstract

The American College of Chest Physicians (ACCP) published its latest (9th edition) guidelines in February 2012. This document is a valuable reference for all clinicians. In the current article, through the analysis of three clinical cases, the authors review, describe, and analyze the most significant new information from the chapter “VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy”: (1) strategies for clinicians facing the prescription of a new drug during pregnancy with little available data; (2) recommendations about indications of thromboprophylaxis for asymptomatic thrombophilias; and (3) thrombophilia screening and secondary prevention for placental complications.
Abstract 391 | PDF Downloads 135 HTML Downloads 439

References

1. Martin B, Morin C. Connaissances de base sur l’utilisation des medicaments au cours de la grossesse. In: Ferreira E. Grossesse et Allaitement: Guide Thérapeutique. Montréal: Éditions du CHU Sainte- Justine; 2007:35–52.

2. Kwedert SL, Lee, RV. Prescribing for the pregnant patient. In: Lee R, Rosene-Montella KR, Barbour LA, et al., eds. Medical Care of the Pregnant Patient. Philadelphia: McNaughton & Gunn; 2000:69–86.

3. Update on overall prevalence of major birth defects – Atlanta, Georgia, 1978–2005. MMWR Morb Mortal Wkly Rep 2008;57(1):1–5.

4. Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform risk? Am J Obstet Gynecol 2002;187:333–9.

5. Xarelto (rivaroxaban) product characteristic summary. Electronic Medicines Compendium. http://www.medicines.org.uk/EMC/medicine/ 21265/SPC/Xarelto+10+mg+film-coated+tablets/#PRECLINICAL_SAFETY. Accessed October 30, 2012.

6. Bayer Schering Pharma AG. Summary of product characteristics: rivaroxaban. Date of text revision: June 2012.

7. Bates SM, Greer IA, Middledorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012;141(2 Suppl):e691S–736S.

8. Rodger MA, Kahn SR, Cranney A, et al. TIPPS investigators. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 2007;5(8):1600–6.

9. Byrd LM, Shiach CR, Hay CRM, Johnston TA. Osteopenic fractures in pregnancy: is low molecular weight heparin (LMWH) implicated? J Obstet Gynaecol 2008;28(5):539–42.

10. Greer IA, Nelson-Piercy C, Greer IA, Nelson-Piercy C. Low-molecularweight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;1062:401–7.

11. Bank I, Libourel EJ, Middeldorp S, et al. High rate of skin complications due to low molecular-weight heparins in pregnant women. J Thromb Haemost 2003;1(4):859–61.

12. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001;1851:148–52.

13. Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169(6):610–5.

14. Robertson L, Wu O, Langhorne P, et al. Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005;132(2):171–96.

15. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996;125(12):955–60.

16. Kent N, Leduc L, Crane J, et al. Prevention and treatment of venous thromboembolism (VTE) in obstetrics. J SOGC 2000;22(9):736–49.

17. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311– 5.

18. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999;94:595–9.

19. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001;108:56–60.

20. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based case-control study. Am J Obstet Gynecol 2008;198:233.e1–7.

21. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001;184:104–10.

22. Larsen TB, Sorensen HT, Gislum M, Johnsen SP. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb Res 2007;120:505–9.

23. Knight M. Antenatal pulmonary embolism: risk factors, management and outcomes. UKOSS. BJOG 2008;115:453–61.

24. Lockwood C, Wendel G. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol 2011;118(3):730–40.

25. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78(4):1183– 8.

26. Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women. J Thromb Haemost 1990;63(2):319–20.

27. Rheaume, M, Durand M, Weber F, Mahone M. Risk of pregnancy-related VTE in asymptomatic women with AT deficit. A systemic review. Poster presentation at NASOM meeting, Québec City, 2012.

28. Rodger MA, Betancourt MT, Clark P, et al. The association of factor V Leiden and prothrombin gene mutation and placenta-related pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010;7(6):e1000292.

29. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33(11):2214–21.

30. Abou-Nassar K, Carrier M, Ramsay T, et al. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. Thromb Res. 2011;128:77–85.

31. Do Prado AD, Piovesan DM, Staub HL, et al. The association between anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 2010;116(6):1433.

32. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;2:CD004659. DOI: 10.1002/14651858.CD004659.pub2.

33. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–14.

34. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of lowmolecular- weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162–7.

35. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586–96.

36. Mello G, Paretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005;45(1):86–91.

37. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized control trial. J Thromb Haemost 2009;7(1):58–64.

38. Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010;104(4):771–9.

39. Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomized controlled NOHPE trial. Thromb Haemost 2011;106(6):1053–61.

40. De Vries JIP, Van Pampus MG, Hague WM, et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset preeclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2011;10(1):64–72.

41. Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012;119(14):3269–75.

42. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and Lactation, 9th edition. Philadelphia: Lippincott, Williams & Wilkins; 2008.